Executive Summary (Q3 2024 ACU): Acme United reported third-quarter revenue of $48.2 million, down 4% versus the prior year, largely reflecting the December 2023 sale of the Camillus and Cuda lines, which reduced quarterly top-line by a non-operational amount. Excluding Camillus/Cuda, Q3 revenue rose 4%, underscoring the resilience of the core First Aid, Westcott, and DMT portfolios. Net income climbed 3% to $2.23 million, while diluted EPS declined to $0.54 from $0.58, driven by a higher weighted average share count used for the period. The company’s gross margin stood at 38.5% in Q3 (38.7% prior year) and expanded to 39.4% for the first nine months of 2024 (versus 37.3% in 2023), aided by manufacturing and distribution productivity. Operating margin was 6.07% in Q3 (6.07% implied), with nine-month margins trending higher due to mix and productivity gains. Free cash flow for the trailing nine months was $7.52 million, and cash flow from operations was $8.87 million, supporting a leverage reduction over the period. Management reaffirmed a constructive outlook, signaling continued earnings and cash-flow strength, balance-sheet strengthening, and active pursuit of accretive acquisitions. The company also highlighted ongoing productivity improvements, automation investments, and strategic product-line integrations (notably Elite First Aid) to broaden high-margin offerings and improve replenishment capabilities via RFID-enabled kits. The remaining year may witness continued growth in the Westcott and DMT lines, though macro uncertainty and customer-channel softness pose near-term headwinds in select segments.